Pharmacogenetics: from bench to byte--an update of guidelines

J J Swen; M Nijenhuis; A de Boer; L Grandia; A H Maitland-van der Zee; H Mulder; G A P J M Rongen; R H N van Schaik; T Schalekamp; D J Touw; J van der Weide; B Wilffert; V H M Deneer; H-J Guchelaar

doi:10.1038/clpt.2011.34

Pharmacogenetics: from bench to byte--an update of guidelines

J J Swen, M Nijenhuis, A de Boer, L Grandia, A H Maitland-van der Zee, H Mulder, G A P J M Rongen, R H N van Schaik, T Schalekamp, D J Touw, J van der Weide, B Wilffert, V H M Deneer, H-J Guchelaar

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

Original language	English
Pages (from-to)	662-673
Number of pages	12
Journal	Clinical Pharmacology and Therapeutics
Volume	89
Issue number	5
DOIs	https://doi.org/10.1038/clpt.2011.34
Publication status	Published - 2011

Keywords

Animals
Aryl Hydrocarbon Hydroxylases
Cytochrome P-450 CYP2C9
Drug Administration Schedule
Drug-Related Side Effects and Adverse Reactions
Humans
Pharmaceutical Preparations
Pharmacogenetics
Practice Guidelines as Topic

Access to Document

10.1038/clpt.2011.34

Cite this

Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., van der Weide, J., Wilffert, B., Deneer, V. H. M., & Guchelaar, H.-J. (2011). Pharmacogenetics: from bench to byte--an update of guidelines. Clinical Pharmacology and Therapeutics, 89(5), 662-673. https://doi.org/10.1038/clpt.2011.34

@article{4b44204dbafd4f24992f512dc88de764,

title = "Pharmacogenetics: from bench to byte--an update of guidelines",

abstract = "Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).",

keywords = "Animals, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 CYP2C9, Drug Administration Schedule, Drug-Related Side Effects and Adverse Reactions, Humans, Pharmaceutical Preparations, Pharmacogenetics, Practice Guidelines as Topic",

author = "Swen, {J J} and M Nijenhuis and {de Boer}, A and L Grandia and {Maitland-van der Zee}, {A H} and H Mulder and Rongen, {G A P J M} and {van Schaik}, {R H N} and T Schalekamp and Touw, {D J} and {van der Weide}, J and B Wilffert and Deneer, {V H M} and H-J Guchelaar",

year = "2011",

doi = "10.1038/clpt.2011.34",

language = "English",

volume = "89",

pages = "662--673",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "5",

}

Swen, JJ, Nijenhuis, M, de Boer, A, Grandia, L, Maitland-van der Zee, AH, Mulder, H, Rongen, GAPJM, van Schaik, RHN, Schalekamp, T, Touw, DJ, van der Weide, J, Wilffert, B, Deneer, VHM & Guchelaar, H-J 2011, 'Pharmacogenetics: from bench to byte--an update of guidelines', Clinical Pharmacology and Therapeutics, vol. 89, no. 5, pp. 662-673. https://doi.org/10.1038/clpt.2011.34

TY - JOUR

T1 - Pharmacogenetics

T2 - from bench to byte--an update of guidelines

AU - Swen, J J

AU - Nijenhuis, M

AU - de Boer, A

AU - Grandia, L

AU - Maitland-van der Zee, A H

AU - Mulder, H

AU - Rongen, G A P J M

AU - van Schaik, R H N

AU - Schalekamp, T

AU - Touw, D J

AU - van der Weide, J

AU - Wilffert, B

AU - Deneer, V H M

AU - Guchelaar, H-J

PY - 2011

Y1 - 2011

N2 - Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

AB - Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

KW - Animals

KW - Aryl Hydrocarbon Hydroxylases

KW - Cytochrome P-450 CYP2C9

KW - Drug Administration Schedule

KW - Drug-Related Side Effects and Adverse Reactions

KW - Humans

KW - Pharmaceutical Preparations

KW - Pharmacogenetics

KW - Practice Guidelines as Topic

U2 - 10.1038/clpt.2011.34

DO - 10.1038/clpt.2011.34

M3 - Article

C2 - 21412232

SN - 0009-9236

VL - 89

SP - 662

EP - 673

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 5

ER -

Pharmacogenetics: from bench to byte--an update of guidelines

Abstract

Keywords

Access to Document

Fingerprint

Cite this